The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis



Sahebkar, Amirhossein, Serban, Maria-Corina, Penson, Peter ORCID: 0000-0001-6763-1489, Gurban, Camelia, Ursoniu, Sorin, Toth, Peter P, Jones, Steven R, Lippi, Giuseppe, Kotani, Kazuhiko, Kostner, Karam
et al (show 3 more authors) (2017) The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. DRUGS, 77 (11). pp. 1187-1197.

[thumbnail of The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations Systematic Review and Meta-Analysis.pdf] Text
The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations Systematic Review and Meta-Analysis.pdf - Published version

Download (893kB) | Preview

Abstract

<h4>Introduction</h4>Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied.<h4>Aims</h4>We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies.<h4>Methods</h4>This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate.<h4>Results</h4>Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD -0.41, 95% confidence interval -0.68 to -0.14, p = 0.003). This effect was robust in the sensitivity analysis.<h4>Conclusions</h4>Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.

Item Type: Article
Uncontrolled Keywords: Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, Cell Line, Tumor, Humans, Breast Neoplasms, Tamoxifen, Selective Estrogen Receptor Modulators, Lipoprotein(a), Female, Randomized Controlled Trials as Topic
Depositing User: Symplectic Admin
Date Deposited: 02 Dec 2019 15:45
Last Modified: 19 Jan 2023 00:17
DOI: 10.1007/s40265-017-0767-4
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3064463